국가: 캐나다
언어: 영어
출처: Health Canada
BETAMETHASONE (BETAMETHASONE DIPROPIONATE); SALICYLIC ACID
ORGANON CANADA INC.
D07XC01
BETAMETHASONE
0.5MG; 30MG
OINTMENT
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5MG; SALICYLIC ACID 30MG
TOPICAL
15G/50G
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0215695004; AHFS:
APPROVED
2021-04-16
_DIPROSALIC_ _®_ _ Lotion and Ointment (Betamethasone Dipropionate and Salicylic Acid) _ _ _ _Page 1 of 15_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DIPROSALIC ® Betamethasone Dipropionate and Salicylic Acid Lotion Betamethasone Dipropionate and Salicylic Acid Ointment Betamethasone 0.5 mg/g (as Betamethasone Dipropionate) and Salicylic Acid 20 mg/g Betamethasone 0.5 mg/g (as Betamethasone Dipropionate) and Salicylic Acid 30 mg/g 60 mL topical lotion 50 g topical ointment Topical Corticosteroid and Keratolytic ORGANON CANADA INC. 16766 route Transcanadienne Kirkland, Quebec H9H 4M7 www.organon.ca Date of Initial Approval: October 04, 1982 Date of Revision: April 15, 2021 Submission Control No.: 249786 _ _ _DIPROSALIC_ _®_ _ Lotion and Ointment (Betamethasone Dipropionate and Salicylic Acid) _ _ _ _Page 2 of 15_ TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................3 1 INDICATIONS ....................................................................................................................3 1.1 Pediatrics ....................................................................................................................3 1.2 Geriatrics ....................................................................................................................3 2 CONTRAINDICATIONS ..................................................................................................3 3 DOSAGE AND ADMINISTRATION ...............................................................................3 3.1 Dosing Considerations ...............................................................................................3 3.2 Recommended Dose and Dosage Adjustment ...........................................................3 4 MISSED DOSE ...................................................................................... 전체 문서 읽기